Hiroki Takeuchi
ABSTRACT
Myopathy is a rare disease lacking a fundamental therapy. Several genetic factors are involved in myopathy; those caused by mutations in FHL1 are rare. We performed molecular dynamics simulation of the LIM2 domain in FHL1 (four and a half LIM domain protein 1). We simulated a partial system consisting of only the LIM2 domain for the wild-type and C101F mutant to confirm the structural stability. We found that structural changes and fluctuations were larger for the mutant type than for the wild-type. Therefore, mutant type structures are unstable in water when the mutations are in residues constituting the zinc finger. Similar results were observed in the simulation of the LIM1+LIM2 domain.
- Komagamine, T., Kawai, M., Kokubun, N., Miyatake, S., Ogata, K., Hayashi, Y., Nishino, I., and Hirata, K. Selective muscle involvement in a family affected by a second LIM domain mutation of FHL1: An imaging study using computed tomography. J. Neurol. Sci. 318 (2012), 163--167.Google Scholar
Cross Ref
- Shathasivam, T., Kislinger, T., and Gramolini., O. A. Genes proteins and complexes: The multifaceted nature of FHL family proteins in diverse tissues. J. Cell. Mol. Med. 14 (2010), 2702--2720.Google ScholarCross Ref
- Schessl, J., Feldkirchner, S., Kubny, C., and Schoser, B. Reducing body myopathy and other FHL1-related muscular disorders.Semin. Pediatr. Neurol. 18 (2011), 257--263.Google ScholarCross Ref
- Cowling, S. B., Cottle, L. D., Wilding, R. B., D'Arcy, E. C., Mitchell, A. C., and McGrath, J. M. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: A comprehensive review of the clinical, histological and pathological features. Neuromuscul. Disord. 21 (2011), 237--251.Google ScholarCross Ref
- Hu, L. Y. R., Ackermann, A. M., and Kontrogianni-Konstantopoulos, A. The sarcomeric M-region: A molecular command center for diverse cellular processes. Biomed. Res. Int. (2015), 1--25.Google ScholarCross Ref
- Tsugawa, J., Ohyagi, Y., Hayashi, Y. K., Nishino, I., and Kira, J. I. A case of adult-onset reducing body myopathy presenting a novel clinical feature, asymmetrical involvement of the sternocleidomastoid and trapezius muscles. J. Neurol. Sci. 343 (2014), 206--210.Google ScholarCross Ref
- Selcen, D., Bromberg, B. M., Chin, S. S., and Engel, G. A. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology. 77 (2011), 1951--1959.Google ScholarCross Ref
- Chen, H. D., Raskind, H. W., Parson W. W., Sonnen A. J., Vu, T., Zheng, L. Y., Matsushita, M., Wolff, J., Lipe, H., and Bird, D. T. A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structual study of FHL1 mutations. J. Neurol. Sci. 296 (2010), 22--29.Google ScholarCross Ref
- Peters, B. M., Yang, Y., Wang, B., Füsti-Molnár, L., Weaver, N. M., and Merz, M. K. Structural survey of zinc-containing proteins and development of the zinc AMBER force field (ZAFF). J. Chem. Theory Comput. 6 (2010), 2935--2947.Google ScholarCross Ref
- Qin, X. R., Nagashima, T., Hayashi, F., and Yokoyama, S. Solution structure of the second LIM domain of skeletal muscle LIM protein 1 (database on the Internet). (2005). available from: http://www.pdb.org/pdb/explore.do?structureId=1X63.Google Scholar
- Niraula, T. N., Koshiba, S., Inoue, M., Kigawa, T., and Yokoyama, S. Solution structure of the skeletal muscle LIM protein 1 (database on the Internet). (2005). available from: http://www.pdb.org/pdb/explore.do?structureId=2cup.Google Scholar
- Webb, B., and Sail, A. Comparative protein structure modeling using modeller. Curr. Protoc. Bioinformatics. (2014), 5.6.1--5.6.32. http://www.expasy.org/spdbv.Google Scholar
- Marti-Renom, A. M., Stuart, A., Fiser, A., Sánchez, R., Melo, F., and Sali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29 (2000), 291--325.Google ScholarCross Ref
- Sali, A., and Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993), 779--815.Google ScholarCross Ref
- Fiser, A., Do, K. R., and Sali, A. Modeling of loops in protein structures, Protein Science. 9 (2000), 1753--1773. https://salilab.org/modeller.Google ScholarCross Ref
- Guex, N., and Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis. 18 (1997), 2714--2723.Google ScholarCross Ref
- Case, A. D., Cerutti, S. D., Cheatham, E. T., III, Darden, A. T., Duke, E. R., Giese, J. T., Gohlke, H., Goetz, W. A., Greene, D., Homeyer, N., Izadi, S., Kovalenko, A., Lee, S. T., LeGrand, S., Li, P., Lin, C., Liu, J., Luchko, T., Luo, R., Mermelstein, D., Merz, M. K., Monard, G., Nguyen, H., Omelyan, I., Onufriev, A., Pan, F., Qi, R., Roe, R. D., Roitberg, A., Sagui, C., Simmerling, L. C., Botello-Smith, M. W., Swails, J.,Walker, C. R., Wang, J., Wolf, M. R., Wu, X., Xiao, L., York, M. D., and Kollman, A. P. (2017), AMBER 2017, University of California, San Francisco.Google Scholar
- Berendsen, C. J. H., Spoel, D. V. D., and Drunen V. R. GROMACS: A message-passing parallel molecular dynamics implementation. Comp. Phys. Comm. 91 (1995), 43--56.Google ScholarCross Ref
- Lindahl, E., Hess, B., and Spoel D.V.D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Model. 7 (2001), 306--317.Google Scholar
- Spoel, D. V. D., Lindahl, E., Hess, B., Groenhof, G., Mark, E. A., and Berendsen, C. J. H. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26 (2005), 1701--1718.Google ScholarCross Ref
- Hess, B., Kutzner, Carsten., Spoel D.V. D., and Lindahl, E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4 (2008), 435--447.Google ScholarCross Ref
- Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P.,Apostolov, R., Shirts, R. M., Smith, C. J., Kasson, M. P., Spoel, D. V. D., Hess, B., and Lindahl, Erik. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 29 (2013), 845--854. Google ScholarDigital Library
- Páll, S., Abraham, J. M., Kutzner, C., Hess, B., and Lindahl, Erik. Tacking exascale software challenges in molecular dynamics simulations with GROMACS. Proc of EASC 2015 LNCS. 8759 (2015), 3--27.Google Scholar
- Abraham, J. M., Murtola, T., Schulz, Roland., Páll, S., Smith, C. J., Hess, B., and Lindahl, Eric. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 1-2 (2015), 19--25.Google ScholarCross Ref
Index Terms
- Simulation Study for Wild-Type and C101F Mutant of LIM2 Domain in FHL1
Recommendations
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR
AbstractMutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR), including L858R/T790M double and L858R/T790M/C797S triple mutations, are major causes of acquired resistance towards EGFR targeted drugs. In this work, a ...
Graphical abstractDisplay Omitted
Cavities create a potential back door in epoxide hydrolase Rv1938 from Mycobacterium tuberculosis-A molecular dynamics simulation study
Display Omitted MD simulation of epoxide hydrolase, Rv1938 from Mtb was carried out for 100ns.Additional new cavities apart from the substrate binding pocket have been identified.These cavities which are located behind the active site may behave as a ...
In silico study of porphyrin-anthraquinone hybrids as CDK2 inhibitor
mono-H2PyP-AQ in the binding pocket of CDK2.Display Omitted Porphyrin-anthraquinone hybrids were designed and evaluated for their CDK2 inhibitory activity.All porphyrin hybrids interacted with key residues in the ATP-binding site of CDK2.The predicted ...
Comments